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Abstract
Background: BMPs are currently receiving attention for their role in tumorigenesis and tumor progression. Currently, most
BMP expression studies are performed on carcinomas, and not much is known about the situation in sarcomas.
Methodology/Principal Findings: We have investigated the BMP expression profiles and Smad activation in clones from
different spontaneous canine mammary tumors. Spindle cell tumor and osteosarcoma clones expressed high levels of BMPs,
in particular BMP-2, -4 and -6. Clones from a scirrhous carcinoma expressed much lower BMP levels. The various clones
formed different tumor types in nude mice but only clones that expressed high levels of BMP-6 gave bone formation.
Phosphorylated Smad-1/5, located in the nucleus, was detected in tumors derived from clones expressing high levels of
BMPs, indicating an active BMP signaling pathway and BMP-2 stimulation of mammary tumor cell clones in vitro resulted in
activation of the Smad-1/5 pathway. In contrast BMP-2 stimulation did not induce phosphorylation of the non-Smad
pathway p38 MAPK. Interestingly, an increased level of the BMP-antagonist chordin-like 1 was detected after BMP
stimulation of non-bone forming clones.
Conclusions/Significance: We conclude that the specific BMP expression repertoire differs substantially between different
types of mammary tumors and that BMP-6 expression most probably has a biological role in bone formation of canine
mammary tumors.
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Introduction
Bone morphogenetic proteins (BMPs), members of the TGF-b
superfamily, constitute a group of extracellular factors that are
important in many cellular processes. Originally they were named
due to their ability to induce bone formation [1], but it is now well
recognized that BMPs can participate in numerous other processes
[2]. To date, approximately 15 BMPs have been identified and
characterized [3]. The BMPs can be divided into two subclasses,
with BMP-2 and -4 belonging to one subclass and BMP-5, -6, -7,
and -8 to another [4]. BMPs signal via type I and -II cell surface
receptors [5] and the signal is transduced via phosphorylation of
Smad-1, -5 and -8 proteins, followed by nuclear translocation of
the phosphorylated Smad [6].
The different BMPs have distinct functions during development
[7]. For example, when the osteogenic activity of 14 types of BMPs
was studied in vivo, BMP-6 and -9 induced a more robust and
mature ossification than the others [8]. Although BMPs have
important functions during physiological bone formation [3,9],
BMPs are also implicated in the formation of bone tumors [10].
Further, there is currently an interest for BMPs in relation to
mammary tumors, [11,12] and metastases derived from human
breast cancer often localize to bone [13], whereas this is
uncommon in dogs [14,15]. Moreover, it is known that mixed
mammary tumors of canine origin often are associated with bone
formation[14].
In a recent study, the expression of BMPs and BMP receptors in
human mammary carcinoma was studied [12]. However, the
expression of BMPs in mammary tumors of non-epithelial origin,
e.g. osteosarcoma or spindle cell tumors, have not been studied.
Further, previous investigations relating to the role of BMPs in
tumorigenesis have mostly focused on a limited number out of the
various BMPs. Moreover, the functionality of the BMP pathway in
tumor tissue has not been studied extensively. Finally, the possibility
that the BMP expression pattern is tumor phenotype-specific has
not been addressed. In this study we addressed all of these issues.
Materials and Methods
Cell lines
The cell line CMT-U353B, established from a poorly
differentiated combined canine mammary osteosarcoma was used
together with cell line CMT-U353H4 established from a canine
mammary simple scirrhous carcinoma [16]. We also used the cell
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tumor [17]. The cell lines were cloned (after passage 16, CMT-
U353 H4; passage 22, CMT-U353 B; passage 15, CMT-U309) by
seeding approximately 30 cells per 10 cm cell culture dish. Cell
colonies were transferred to new plates and further cultivated. The
cell lines and clones were cultured in RPMI 1640 medium
(Invitrogen, Carlsbad, CA), supplemented with 2 mM L-Gluta-
mine (SVA, Uppsala, Sweden), 10% fetal bovine serum (Invitro-
gen, Carlsbad, CA), penicillin (120 mg/ml) and streptomycin
(100 mg/ml; SVA).
Ribonuclease protection assay (RPA)
Total RNA was isolated from cell cultures of the clones
(passages 5–7) using RNAeasy midi kits (Qiagen sciences,
Maryland). RPA was performed using a mouse multi-probe
BMP set (RiboQant system; BD Biosciences, Pharmingen, CA)
that detected BMP -1, -2, -3, -3B, -4, -5, -6, -7, -8A and -8B,
including L32 and GAPDH as internal controls. For each analysis,
15 mg of RNA was used. The protected fragments were separated
on a 6% acrylamide, acrylamide/bis-acrylamide 19:1, 7 M Urea
and 16TBE gel (Severn Biotech, UK). The gel was dried and
exposed to a Biomax MR film (Kodak) for 1 to 4 days.
Tumorigenicity in nude mice
Five clones from each cell line were subcutaneously inoculated
in female Balb/c nu/nu mice (6 weeks; Bomholtgaard, Denmark)
[16]. The cells (passages 4–9) were suspended in 100 ml PBS and
were inoculated subcutaneously in the flank of the animal. If no
tumor formation was observed after one month in any of the mice
injected with the same clone, the group received a second injection
in the other flank. Mice injected with the same clone but lacking
sign of tumor growth one month after the second injection
received a final injection (1610
7 cells in 100 ml PBS) subcutane-
ously in the lumbar region. The animal experiments were
performed in accordance with protocols approved by the local
ethical committee, approval number C135/3.
Immunohistochemistry
Tissues were fixed in 4% buffered formalin. Bone tissues were
decalcified and embedded in paraffin. A tissue microarray (TMA)
[18] was prepared with the tumors generated from the CMT-
U353 B clones. Two ø 1 mm punches were manually obtained
from each tumor, transferred into one recipient TMA (Beecher
Instruments, Silver Spring, MD, California), and baked in 60uCi n
1 h. The TMA was sectioned (Microm HM 355 S; Microm,
Walldorf, Germany) and put on SuperfrostHPlus Gold slides
(Menzel GmbH & Co KG, Braunschweig, Germany). Other
tumor and control tissues without osseous areas, were put on
SuperfrostHPlus slides (Menzel GmbH & Co KG, Braunschweig,
Germany). The 5 mm sections were baked in 37uC overnight and
1 h in 60uC. For antigen retrieval, the slides were placed in
0.02 M citrate buffer, pH 6.0 (PS1 antibody) or Target Retrieval
Solution (Dako, Glostrup, Denmark) and boiled in a decloaking
chamber (Biocare Medical). The following antibodies were used: a
polyclonal antibody against phosphorylated Smad-1/5 (PS1)[19],
a BMP-6 antibody (ab15640, Abcam, Cambridge, UK) and a
polyclonal BMP-2/4 antibody (AF355, R&D systems, Europe Ltd,
Abingdon, UK). The slides were incubated in 1% H2O2 in
methanol for 30 min at room temperature prior to the BMP-6
antibody incubation. All slides were incubated overnight with the
primary antibody at +4uC. For the stainings, the ABC-Elite system
(Vector laboratories, CA, USA) and NovaRED (Vector laborato-
ries) were used. To test the specificity of the PS1 antibody, a
blocking peptide was used [19]; an excess of peptide (1.2 ng/ml)
was incubated for 7 h with PS1 at 4uC before being incubated
with the tissue sections. For every immunohistochemical analysis,
positive and negative controls were used. Canine mammary gland,
as well as the human breast cancer cell line MDA-MB-231 were
used as positive controls for the BMP-6 antibody and canine rib
joint was used as positive control for the BMP-2/4 antibody. For
polyclonal antibodies, Tris buffered saline was used as negative
control. As negative control for the monoclonal BMP-6 antibody,
unspecific antibodies of IgG1 isotype were used.
In vitro BMP stimulation
Canine mammary tumor cell clones and as a positive control
HTh 74 cells, an anaplastic thyroid carcinoma cell line [20] were
stimulated with BMP-2. Cells (80–100% confluent) were incubated
overnight in RPMI 1640 (canine clones) or Eagle’s minimal
essential medium (HTh 74) with 0.5% fetal bovine serum.
Subsequently, cell cultures were stimulated with 250 ng/ml
BMP-2 (Peprotech, London, UK) in PBS/1.3% BSA for 1 h
(37uC). Negative controls were incubated with PBS/1.3% BSA.
Western blot
Cells were solubilized in cell lysis buffer (1% Triton X-100,
150 mM NaCl, 10 mM Tris-HCl pH 7.4, 1 mM EGTA, 1 mM
EDTA and 0.5% NP-40) containing protease and phosphatase
inhibitors (35 ng/ml phenylmethylsulfonyl fluoride (PMSF),
1m MN a 3VO4 and 1.4 mg/ml aprotinin). Lysates were incubated
30 min on ice and centrifuged 15 min at 15,000 x g (4uC). The
samples were separated by gradient SDS-PAGE followed by
transfer nitrocellulose filters. Filters were blocked with 5% BSA in
TBS-T (10 mM Tris-HCl, pH 7.7, 0.15 M NaCl, 2% Tween-20)
overnight. The filters were probed with antibodies to: Smad-5
[21], phosphorylated Smad-1/5 (PS1) (kind gift from Aristidis
Moustakas, LICR, Uppsala, Sweden), Chordin-like 1 (MAB1808,
R&D systems Europe Ltd, Abingdon, UK), p38a (#9217, Cell
Signaling Technology, Beverly, MA), phosphorylated p38 (Phos-
pho-p38 #9216, Cell Signaling Technology, Beverly, MA) and
Smad-7 (kind gift from Mare ´ne Landstro ¨m, LICR, Uppsala,
Sweden). The human prostate cancer cells PC-3U (kind gift from
Mare ´ne Landstro ¨m, LICR, Uppsala, Sweden) were used as
positive control for the P-p38, p38 and Smad-7 experiments.
For the PS1 antibody, the specificity was verified by peptide
blocking [19] (1.2 ng/ml of peptide; overnight incubation) before
incubation with filters. Polyclonal a-Smad-5 antibody [21] and b-
Actin (A5441, Sigma-Aldricht, St Louis, MO) were used as loading
controls. Filters were incubated with antibodies at room
temperature (1 h). HPR-conjugated anti-rabbit Ig (GE Health-
care, UK) was used as secondary antibody and a commercial kit,
Super SignalH, with enhanced chemiluminescence (ECL) (Pierce,
Rockford, IL) was used to visualize the results. Filters were
stripped with a buffer containing 100 mM b-mercaptoethanol, 2%
SDS and 62.5 mM Tris-HCl, pH 6.7.
Results
To study the BMP expression profile in mammary tumors of
different types, cell lines were established from a spindle cell tumor
(CMT-U309), an osteosarcoma (CMT-U353B) and a scirrhous
carcinoma (CMT-U353 H4) of canine origin. Subsequently, as
detailed in Table 1, a number of clones were established from the
parent cell lines.
RPA analysis showed that the osteosarcoma clones all expressed
high levels of different BMPs (Figure 1B). In particular, high levels
of BMP-4 were seen. Moreover, all of the clones, except CMT-
U353B clone 6, expressed high levels of BMP-6 while BMP-2
BMBs in Canine Mammary Tumors
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was unevenly expressed between the clones (Figure 1B). BMP-8
expression levels were low but similar in all osteosarcoma clones.
BMP-1 and -3 expression was not detected in any of the clones,
whereas low levels of BMP-7 appeared to be expressed by clone 3.
Because the primary spindle cell tumor did not form bone [17], it
may be expected that the clones derived from it did not express
high levels of BMPs. However, as shown in Figure 1A, we detected
expression of BMP-2, -4, -5, and -6, although the expression
profile and levels of expression varied among the different spindle
cell clones. Notably, one of the spindle cell clones (clone A5)
showed very low levels of BMP expression, although BMP-4 was
Table 1. Tumors from cloned cell lines CMT-U309, CMT-U353 B and CMT-U353 H4 inoculated in mice.
Clone identity Tumor take Tumor type
CMT-U309 clone 1 0/5 No tumors formed
2 0/5 No tumors formed
4 3/5 Spindle-cell tumors (2), Spindle-cell tumor with bone formation (1)
A5 0/5 No tumors formed
C6 3/5 Spindle-cell tumors with bone formation (2), Spindle-cell tumor (1)
CMT-U353 B clone 1 5/5 Osteosarcomas
2 4/5 Osteosarcomas
3 0/5 No tumors formed
6 3/5 Spindle-cell tumors
7 4/5 Osteosarcomas
CMT-U353 H4 clone 5 3/5 Spindle-cell tumors (2), Fibroma durum (1)
6 4/5 Spindle-cell tumors
9 1/5 Anaplastic tumor
10 4/5 Spindle-cell tumors
12 1/5 Spindle-cell tumor
doi:10.1371/journal.pone.0007133.t001
Figure 1. RPA analysis of expressed BMP mRNA in canine mammary clones. (A) Spindle cell clones (CMT-U309), (B) osteosarcoma clones
(CMT-U353 B) and (C) scirrhous carcinoma clones (CMT-U353 H4).
doi:10.1371/journal.pone.0007133.g001
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expected low levels of BMP expression. Indeed, the various
carcinoma clones expressed BMPs at low levels (Figure 1C).
We next asked how the various BMP expression patterns
correlate with formation of tumors in vivo. Clones were inoculated
into nude mice and tumors were allowed to form (Table 1).
Notably, several of the clones did not produce tumors in vivo:
CMT-U309 (clones 1, 2, A5), CMT-U353B (clone 3). Inoculation
of spindle cell clones (CMT-U309) gave rise to spindle cell tumors
and, noteworthy, bone formation was seen in half of the cases
(Table 1). Interestingly, the CMT-U309 clones, 4 and C6, that
formed bone tumors in the mice expressed BMP-6 (Figure 1).
Inoculation of osteosarcoma clones (CMT-U353 B) produced
osteosarcomas but, in one case (clone 6), spindle cells tumors were
instead generated. Finally, inoculation of carcinoma clones (CMT-
U353 H4) resulted in formation of either spindle cell-, fibroma
durum- or anaplastic tumors, and in no case was bone formation
seen (Table 1).
In the next set of experiments we investigated whether the BMP
expression was reflected by activated BMP signaling pathways, by
analyzing for Smad-1/5 phosphorylation [6]. For this purpose, an
antibody that recognizes both phosphorylated Smad-1 (P-Smad-1)
and P-Smad-5 was used. As shown in Figure 2A, tumors derived
from spindle cell clones were positive for P-Smad-1/5, particularly
in the vicinity of bone (Figure 2A and results not shown), but also
in the spindle cell area (Figure 2B). Notably, P-Smad-1/5 was
primarily located in the nucleus, in agreement with translocation
of P-Smad-1/5 in to the nucleus [6]. The experimental tumors
from the osteosarcoma clones showed strong staining for P-Smad-
1/5, in particular at the edges of the tumor. The degree of P-
Smad-1/5 staining varied among the different clones, with clones
2 (Figure 2D) and 7 (Figure 2E) showing stronger staining than
clone 6 (Figure 2F). All of the tumors derived from the scirrhous
carcinoma clones were only weakly positive for P-Smad-1/5
(Figure 2G-I).
To further verify that the Smad-1/5 pathway is activated in the
mammary tumors, tumor cells were stimulated with BMP followed
by detection of P-Smad-1/5 by Western blot analysis. One clone
showing high levels of BMP expression (CMT-U309, clone 4; see
Figure 1) and one clone showing low BMP expression (CMT-
U353 H4, clone 12; see Figure 1) were stimulated with BMP-2. As
a positive control, the human anaplastic thyroid carcinoma cell
line HTh 74, known to respond to BMP stimulation [22], was
included. As shown in Figure 3, all of the three cell lines responded
to BMP-2 stimulation by Smad 1/5 phosphorylation. Strikingly,
the clone with the highest level of BMP expression (CMT-U309,
clone 4) showed a much more robust response as compared to the
low BMP-expressing clone (CMT-U353 H4, clone 12). There is
also the possibility that the stimulation with BMP-2 may activate
the p38 pathway, which would be reflected by phosphorylation of
p38 [23,24]. To address this possibility, BMP-2-stimulated CMT-
U309, clone 4 and CMT-U353 H4, clone 12 were also analyzed
for the levels of phosphorylated p38 (P-p38). As shown in Figure 3
these clones indeed expressed p38 protein and it was also evident
that basal phosphorylation of p38 was present. However, BMP-2
stimulation did not cause an increase in the level of P-p38.
Together, these data suggest that BMP-2 preferentially activates
the Smad-1/5 pathway in CMT-U309, clone 4 and CMT-U353
H4, clone 12, causing minimal activation of p38.
The activity of BMPs is stringently regulated by BMP
antagonists such as Chordin-like 1 [25]. A possible explanation
for the different ability of the various clones to generate bone-
containing tumors in vivo could thus be related to differences in
Chordin-like 1 expression. To address this possibility, we therefore
assessed the levels of Chordin-like 1 protein in various clones, and
if the levels were affected by BMP-2 stimulation. As shown in
Figure 4, the levels of Chordin-like 1 in response to BMP-2
stimulation varied markedly among the clones. Strikingly, the
Chordin-like 1 levels were considerably higher in non-tumor
forming clones (CMT-U353 clone 3) and in a clone that formed
tumors without bone (CMT-U353 B clone 6) than in bone-
forming clones (CMT-U353 B clones 2 and 7), (see Table 1).
Hence, these data are compatible with a scenario in which the
bone-generating capacity of the respective clones could be related
to their expression of BMP antagonists.
Further, we have analyzed Smad-7 protein expression, an
inhibitory Smad. The results showed clear expression of Smad-7 in
all clones tested. However, the expression levels were very similar
among the different clones, and there was no correlation between
basal levels of Smad-7 expression and sensitivity to BMP-
stimulation or bone formation (not shown).
Previous studies indicate that, out of the different BMPs, BMP-6
may hold a key position in a number of processes, including bone
formation [26] and wound healing [27]. Next, we therefore
analyzed the various tumors for presence of BMP-6 protein.
Tumors derived from spindle cell clones were strongly positive for
BMP-6 (Figure 5A–B), in agreement with the high mRNA levels
for BMP-6 in the corresponding clones (see Figure 1). Notably, the
staining was particularly strong in the vicinity of bone tissue and
also in the spindle cells forming the major part of the tumor. Also
tumors formed from a high BMP-6-expressing osteosarcoma clone
(CMT-U353 B, clone 2; see Figure 1) showed strong staining for
BMP-6, with particularly strong staining at the edge of the tumor
(Figure 5C). Interestingly, the staining was accentuated at the cell
membranes (Figure 5C; arrow). In contrast, when tumors from an
osteosarcoma clone with low expression of BMP-6 mRNA (CMT
353 B, clone 6; see Figure 1) were analysed, only weak, diffuse
BMP-6 staining was observed (Figure 5D). Unexpectedly, tumors
from scirrhous carcinoma clones, i.e. clones showing low levels of
BMP-6 mRNA expression in vitro (see Figure 1) and a low degree of
Smad-1/5 pathway activation (see Figure 2G-I), were strongly
positive for BMP-6 protein (Figure 5E-F).
Since the RPA analysis revealed strong expression of BMP-2
and -4 in a number of clones, it was of interest to assess whether
the in vitro expression patterns of these BMPs were reflected by
their presence in the tumors formed in vivo from the respective
clones. As shown in Figure 6A and B, the tumor formed by CMT
U309, clone 6, i.e. a clone highly expressing BMP-4 in vitro (see
Figure 1), was strongly positive for BMP-2/4. Strong positivity was
also seen in tumors formed from CMT-U353 B, clones 2
(Figure 6C) and 6 (Figure 6D), i.e. clones with high expression
of BMP-4 (see Figure 1). Similar to the staining for BMP-6 (see
Figure 5C), strong staining for BMP-2/4 was seen particularly in
tissue adjacent to bone (Figure 6C). It is also clear that tumors
formed from CMT-U353 H4, clones 6 and 9 stained less intensely
for BMP-2/4, in agreement with a low expression of BMP-4 and
only modest expression of BMP-2 as judged by the RPA analysis
(see Figure 1).
Discussion
This study is, to our knowledge, the first in which the expression
profile for BMPs in different types of canine mammary tumors is
determined in concert, although some studies have addressed the
expression of individual BMPs in selected types of mammary
tumors and cell lines [12,28–31]. Moreover, previous studies have
mostly addressed the BMP expression in primary tumors and it is
therefore difficult to ascertain whether the specific BMP expression
BMBs in Canine Mammary Tumors
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types present in the primary tumor, or if the total BMP expression
pattern is a result of one single type of cell. To specifically address
the latter issue we here studied the BMP expression profile in cell
clones derived from the respective type of tumor and, to ensure
that the expression pattern found mimics that of the original cell
Figure 2. Immunohistochemical staining for phosphorylated Smad-1 and –5 (P-Smad-1/5). (A–C) Tumors generated by clones from the
cell lines CMT-U309 (spindle cell); (D–F) CMT-U353 B (osteosarcoma); (G–I) CMT-U353 H4 (scirrhous carcinoma). (A–C) Spindle cell tumors generated
by CMT-U309, clone C6. (A) Spindle cell tumor with an area of formed bone (*). Cells adjacent to the bone area and spindle cells with a distance to the
formed bone showed clear positive staining (arrows). (B) Spindle cell tumors with strongly positive cells evenly distributed in the tumor (arrows). (C)
Antibody specificity test: the signal was abolished when the antibody was incubated with blocking peptide. (D–E) Osteosarcomas formed by CMT-
U353 B, clone 2 (D) and 7 (E). P-Smad-1/5 was detected in the cell dense border of the osteosarcomas. Cells closer to the centre of the tumor
produced osteoid (*). (F) Spindle cell tumor generated by CMT-U353 B, clone 6. Bone formation was not seen in any tumors from this clone. P-Smad-
1/5 was detected at lower levels than in tumors from clone 2 and 7, and was evenly distributed in the tumors (arrows). (G–H) Spindle cell tumors
generated by clones from the scirrhous carcinoma: CMT-U353 H4, clone 6 (G), clone 9 (H) and clone 10 (I). Evenly distributed cells positive for P-Smad-
1/5 were seen in the tumors (arrows). Note that positive cells show a predominantly nuclear staining.
doi:10.1371/journal.pone.0007133.g002
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Smad-5 and p38 in mammary tumor clones. CMT-U353 H4 (clone
12), CMT-U309 (clone 4) and HTh 74 (positive control for Smad-1/5
phosphorylation) cells were stimulated with BMP-2 (as indicated) in
vitro and phosphorylation of Smad-1/5 (P-Smad-1, -5) and p38 (P-p38)
was analyzed by Western blot. Immunoblot analysis for total Smad-5,
total p38 and b-Actin was performed as loading controls.
doi:10.1371/journal.pone.0007133.g003
Figure 4. Expression of Chordin-like 1 protein in response to
BMP-2 stimulation analyzed by Western blot. CMT-U353 B (clones
2, 3, 6 and 7) were either non-stimulated or stimulated with BMP-2 as
indicated. b-Actin was used as loading control.
doi:10.1371/journal.pone.0007133.g004
Figure 5. Immunohistochemical analysis for BMP-6. BMP-6 staining
wasperformedintumorsgeneratedbyclonesfromtheCMT-U309(spindle
cell), CMT-U353 B (osteosarcoma) and CMT-U353 H4 (scirrhous carcinoma)
cell lines. (A–B) Spindle cell tumors generated by CMT-U309, clone C6. (A)
Spindle cell tumor with an area of formed bone (*). Cells adjacent to the
bone area and spindle cells further away from the formed bone showed
strong positive cytoplasmic staining (arrows). (B) Spindle cell tumors with
cells strongly positive for BMP-6, evenly distributed in the tumors. (C)
Osteosarcoma formed by CMT-U353 B, clone 2. BMP-6 was detected in the
cell dense border of the osteosarcoma and some cells showed
membranous accentuation of the staining (arrow). (D) Spindle cell tumor
generated by CMT-U353 B, clone 6. Faint staining for BMP-6 was seen
throughout the tumors, with only a few cells with stronger staining and
clear cytoplasmic positivity (arrow). (E–F) Spindle cell tumors generated by
CMT-U353 H4, clone 6 (E) and 9 (F) were positive for BMP-6. Tumor cells
showed cytoplasmic positivity and some cells had membranous
accentuation of the staining (arrow).
doi:10.1371/journal.pone.0007133.g005
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low cell passage numbers.
We show that each of a number of clones from mammary
tumors expresses a panel of different BMPs. We also show that the
BMP expression profile is highly variable, both as regards which
BMPs that are expressed and also as regards the levels of
expression for the various BMPs. Hence, the total BMP expression
pattern within a tumor is probably the result of distinct
contributions from several types of cells types found within an
individual tumor. When comparing the BMP expression profiles of
the different types of mammary tumor clones, we were not able to
see any clear cut differences in either BMP expression repertoire
or expression levels when comparing clones from the spindle cell
and osteosarcoma. In contrast, we show that the scirrhous
carcinoma clones express considerably lower levels of BMP
transcripts than the spindle cell and osteosarcoma clones.
Moreover, the carcinoma cells displayed a more limited repertoire
of BMPs being expressed with, for example, undetectable BMP-5,
-6, -7 and –8 expression. Notably, the expression of the control
gene GAPDH was highly consistent among all clones whereas the
expression of the other used control gene, L32, was consistent
among the osteosarcoma and carcinoma clones but was less
consistent among the spindle cell clones.
An important issue is whether the BMP expression pattern/level
of the various clones can be correlated with tumorigenicity. We
show that 3 of the clones derived from the spindle cell tumor
(CMT-U309, clones 1, 2, A5) were unable to generate tumors in
vivo, after inoculation in nude mice. Out of these, clone 1 and 2
expressed rather high levels of BMPs and it is therefore not
possible to correlate their lack of tumorigenicity with a low general
expression of BMPs. Further, the only clone derived from the
osteosarcoma not being able to form tumors in vivo (clone 3)
expressed very high levels of BMPs (BMP-2, -4, -5, -6) in vitro, thus
further supporting the notion that the BMP expression profile of
the inoculated clones is not a major determinant for tumorigenic-
ity. On the other hand, since the latter clone expressed high levels
of the BMP antagonist, Chordin-like 1, its lack of tumorigenicity
may be related to blocked BMP-mediated pathways.
Considering the strong implication of BMPs, in particular BMP-
6, in both physiological and tumorous bone formation
[8,9,29,30,32,33], it is also of interest to assess whether the
expression pattern/levels of BMPs can be linked to bone formation
in tumors. Interestingly, we found that all of the clones that gave
bone formation expressed high levels of BMP-6 mRNA, whereas
all of the clones that failed to generate bone were low producers of
BMP-6. BMP-2 was expressed at high levels in some bone-
producing clones (CMT-U309, clone 4; CMT-U353 B, clone 7)
but was barely detectable in others (e.g., CMT-U309, clone C6),
suggesting that BMP-2 is not of major importance in tumorous
bone formation. This notion is also supported by a study in which
delivery of BMP-2 via an adenoviral vector failed to give bone
formation in nude rats [32]. BMP-4 was highly expressed in all
bone-forming clones, but was also expressed at rather high levels
in a non-bone generating osteosarcoma clone (clone CMT-U353
B, clone 6) as well as in all of the carcinoma clones. Hence, we
were not able to see a clear link between BMP-4 expression levels
and bone formation. Together, our results are thus compatible
with a scenario in which BMP-6 plays a major role in the
formation of bone in mammary tumors, a finding that is in line
with previous other reports [8,32].
When assessing the levels of BMP-6 protein in the various
tumors we found that tumors derived from high BMP-6-expressing
spindle cell and osteosarcoma clones, as expected, were strongly
positive for BMP-6 protein. Further, tumors formed from the low
Figure 6. Immunohistochemical analysis for BMP-2/4. Staining
for BMP-2/4 was performed in tumors generated by clones from the
CMT-U309 (spindle cell), CMT-U353 B (osteosarcoma) and CMT-U353 H4
(scirrhous carcinoma) cell lines. (A–B) Spindle cell tumors generated by
CMT-U309, clone C6. (A) Spindle cell tumor with an area of formed bone
(*). Cells adjacent to the bone area and spindle cells further away from
the formed bone showed strong positive cytoplasmic staining. (B)
Spindle cell tumors with cells strongly positive for BMP-2/4, evenly
distributed in the tumors. (C) Osteosarcoma formed by CMT-U353 B,
clone 2. BMP-2/4 was detected in the cell dense border of the
osteosarcoma as well as in cells adjacent to bone (*). (D) Spindle cell
tumor generated by CMT-U353 B, clone 6. Strong staining for BMP-2/4
was seen throughout the tumors. (E–F) Spindle cell tumors generated
by CMT-U353 H4, clone 6 (E) and 9 (F) stained less intensely for BMP-2/4.
doi:10.1371/journal.pone.0007133.g006
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were only weakly positive for BMP-6 protein. In contrast, we
unexpectedly found that also tumors derived from the carcinoma
clones, i.e. low producers of BMP-6, were positive for BMP-6
protein. We cannot with certainty explain this apparent discrep-
ancy, although we favor the possibility that the BMP-6 protein
expression in the carcinoma clones may have been upregulated
during the in vivo inoculation process. On the other hand, although
BMP-6 protein is present, the BMP pathway does not appear to be
functional, as shown by the low degree of Smad-1/5 phosphor-
ylation.
In summary, our study shows that BMPs are highly expressed in
cell clones derived from various mammary tumors, thus
implicating BMPs in breast cancer. However, it remains to be
determined if the BMP expression profile of the various clones
exactly matches the BMP profile of the corresponding formed
tumors.
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